drugset / Trial / NCT05221645
Pembrolizumab in Combination With R-ICE Chemotherapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma
Phase 2
Active not recruiting
65 enrolled
University of Southampton
Merck Sharp & Dohme LLC · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
This is an open-label, multicentre, randomised phase II trial in relapsed or refractory diffuse large B-cell lymphoma.
Timeline
- Start
- 2022-06-27
- Primary completion
- 2026-05-30
- Completion
- 2026-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Pembrolizumab | Monoclonal antibody | 200 mg | Intravenous |
| Background | Carboplatin | Small molecule | — | — |
| Background | Etoposide | Small molecule | 100 mg/m2 | — |
| Background | Ifosfamide | Small molecule | 5000 mg/m2 | — |
| Background | Rituximab | Monoclonal antibody | 375 mg/m2 | — |